2023-509510-11-00撤回3 期
QIMPD SUBMISSION ONLY - MorningLyte - A Phase III randomized, open-label, international, multicenter study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma (title noted in the current version of the protocol)
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- N/A
研究概览
简要总结
NA
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
N/A
N/A
次要结局
- N/A
研究者
Clinical Trial Accountable
Scientific
F. Hoffmann-La Roche AG
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Relationship Between Sleep-Wake Quality and Nocturnal Medical OrdersSleep QualityNCT07288775Hospital Clinica Nova51
尚未招募
不适用
WELT-REST: WELT Randomized Evaluation of Sleep TherapyInsomniaNCT07289217WELT corp80
已完成
1 期
A Study to Investigate the Effect of a Low-fat Meal and Evening Dosing on KAI-7535 in Participants Living With Obesity or OverweightObesityNCT07294898Kailera18
尚未招募
不适用
Diactive-1: Scaled-up Personalized mHealth Program for Youth With Type 1 DiabetesNCT07290868Fundacion Miguel Servet158
招募中
1 期
An early Phase 1b Study to assess how safe and effective is the treatment with drugs, called Mosunetuzumab or Glofitamab in Combination with drugs called, CC-220 and CC-99282 in Patients with B-Cell Non-Hodgkin Lymphoma.2023-505185-28-00F. Hoffmann-La Roche AG52